A 54-year-old man with type 2 diabetes was referred to our hospital for endocrine evaluation of acromegaly. Physical examination showed typical acromegalic features without Cushingoid features. Magnetic resonance imaging of the brain revealed the presence of a pituitary macroadenoma. Basal plasma levels of GH and insulin-like growth factor-I under fasting hyperglycemia (202 mg/dl) were markedly elevated. Plasma GH levels paradoxically increased after stimulation with TRH and LH-RH, and decreased after bromocriptine and octreotide administration. Endocrine examination of the hypothalamo-pituitary-adrenal (HPA) axis showed a lack of circadian rhythm of ACTH and cortisol, non-suppressibility to low-dose (1 mg), but suppressibility to high-dose (8 mg) dexamethasone, and normal response to CRH stimulation. The tumor resected by transsphenoidal surgery was histopathologically consistent with the diagnosis of eosinophilic adenoma: positive immunoreactivities of GH, PRL and ACTH were demonstrated, but negative immunoreactivities of prohormone convertase (PC) 1/3 by immunohistochemical method. After surgery, plasma GH and IGF-I levels decreased along with normalization of HPA axis. Metabolic co-morbidities such as diabetes and hypertension disappeared after removal of the pituitary tumor. This is a very rare case of GH-producing pituitary adenoma causing typical acromegaly with concomitant production of ACTH causing subclinical Cushing's disease.
RECENTLY, many cases of adrenal incidentaloma due to cortisol-producing tumors without typical Cushingoid features, termed subclinical/preclinical Cushing's syndrome, have been reported [1] . However, only a few cases of ACTH-producing pituitary adenoma without overt Cushingoid features (subclinical/ preclinical Cushing's disease) have been reported thus far [2] . Furthermore, only 4 cases of pituitary adenoma with concomitant production of both ACTH and GH causing Cushing's disease and acromegaly, respectively, have been reported [3] [4] [5] [6] .
We report herein a very rare case of a pituitary GHproducing adenoma with concomitant ACTH production, leading to the development of typical acromegaly and subclinical Cushing's disease.
Case Report
A 54-year-old man with 10-year history of type 2 diabetes and hypertension was referred to our hospital for further endocrine evaluation of acromegaly.
He was 156 cm tall and weighted 54 kg (body mass index : 22) . Blood pressure was 150/98 mmHg. Physical examination on admission showed typical acromegalic features, such as deep nasolabial furrows, macroglossia, thick lip, and thickening of hands and feet; heel pad thickness was 24 mm. However, he did not have any Cushingoid appearance, such as a moon-face, buffalo hump, central obesity or purple striae. He had neither visual disturbance nor diplopia.
Laboratory data (Table 1) showed a marked glycosuria, hyperglycemia and increased glycated hemoglobin level, indicating poor glycemic control. Endocrine examination revealed that basal plasma GH level (31.5 ng/ml) and insulin-like growth factor (IGF)-I level (493 ng/ml) were both elevated under high fasting plasma glucose level (202 mg/dl), but plasma levels of other pituitary hormones were within normal ranges. Plasma cortisol level and 24-hour urinary excretion of free cortisol, 17-OHCS and 17-KS were also within normal ranges.
Plasma GH levels paradoxically increased after stimulation with LH-RH and TRH, while responses of TSH, PRL and gonadotrophins secretion after TRH and LH-RH stimulation were normal (Fig. 1A, B) . Plasma GH levels decreased from 26.7 to 1.46 ng/ml after oral administration of bromocriptine (2.5 mg), and from 36.6 to 1.32 ng/ml after subcutaneous injection of octreotide (100 µg), respectively (Fig. 1C, D) .
Endocrine examination of the hypothalamo-pituitaryadrenal (HPA) axis showed a lack of circadian rhythm of ACTH and cortisol ( Fig. 2A) , non-suppressibility to low-dose (1 mg), but suppressibility to high-dose (8 mg) dexamethasone (Fig. 2B) , and normal response after CRH stimulation (Fig. 2C) .
Magnetic resonance imaging (MRI) of the head revealed the presence of a pituitary macroadenoma (10 × 8 × 12 mm), without enhancement by gadolinium (Fig. 3A) .
These endocrine and imaging data are compatible with the diagnosis of GH-producing pituitary macroadenoma with possible autonomous production of ACTH.
Transsphenoidal surgery for removal of the pituitary tumor was performed in May 2003. Postoperative course was uneventful without any evidence of residual tumor by pituitary MRI (Fig. 3B) . Basal levels of both ) * GH and IGF-I decreased to 4.33 ng/ml and 217 ng/ml, respectively, while the paradoxical responses of plasma GH by TRH and LH-RH were markedly decreased or abolished, respectively (Fig. 1A, B) , suggesting a residual GH-secreting adenoma. By contrast, improvement in the circadian rhythm of ACTH and cortisol, suppressibility to low-dose dexamethasone, and normal response to CRH stimulation were observed after surgery (Fig. 2) . He was discharged with bromocriptine (2.5 mg) treatment, and his basal GH level was less than 1.0 ng/ ml. The patient's glycemic control (HbA1c level <7.0%) as well as blood pressure (130/80 mmHg) improved 4 months after operation.
Histopathology and immunohistochemistry
Microscopical examination of the resected pituitary tumor specimens is consistent with the pathological diagnosis of eosinophilic adenoma (Fig. 4A ). Immunohistochemical study was performed using the Ventana DAB Universal Kit (Ventana Medical systems, Oro Valley, AZ) and antibodies against GH (1 : 400, Novocastra Laboratories, Newcastle, UK), PRL (1 : 1000, DAKO, Carpinteria, CA), ACTH (1 : 200, Novocastra Laboratories), and prohormone convertase (PC) 1/3 (1 : 400, Chemicon Int., Temecula, CA).
Immunoreactivities for GH and PRL were diffusely positive (Fig. 4B, C) , while that for ACTH was focally positive (Fig. 4D) ; immunoreactivities for PC 1/3 were negative (Fig. 4E) as well as for LH, FSH, TSH (not shown). Positive immunostaining for PC 1/3 was confirmed in the pituitary tumor from a patient with overt Cushing's disease (Fig. 4F) .
Discussion
In the present case, the diagnosis of acromegaly was established based on typical acromegalic features, increased basal plasma GH and serum IGF-I levels even under hyperglycemic state, paradoxical responses of GH to LH-RH and TRH, and the presence of pituitary tumor; this was confirmed by the presence of GH immunoreactivity in tumor specimen by immunohistochemical analysis. GH-producing pituitary adenomas are often accompanied with multi-hormonal production, such as PRL and TSH [7] . However, pituitary adenoma producing both GH and ACTH is extremely rare; only 4 cases have been reported thus far [3] [4] [5] [6] . Thus, the present GH-producing adenoma with concomitant ACTH production adds the fifth case to the literature.
Multi-hormonal pituitary adenomas are divided into two subgroups; monomorphous adenoma consisting of one distinct cell type with two or more hormones produced in the same cell, and bi-(pluri-)morphous adenoma consisting of two or more cell types with each hormone produced in the different cell populations [8] . Since either immunohistochemical study using double staining, electron microscopic study, or clonal analysis was not performed in this case, it remains unknown whether GH, PRL, and ACTH are synthesized in the same or different cells, and whether the tumor cells are monoclonal or polyclonal. It has been reported that two transcription factors, NeuroD1 and Pit-1, are aberrantly co-expressed in the same pituitary tumor cells with ACTH and GH production, respectively [9] , suggesting their potential roles in the differentiation into ACTH-and GH-producing cells. Thus, such translineage co-expression of transcription factors (NeuroD1, Pit-1) may be responsible for the multihormone synthesis as in the present case.
Although immunohistochemical study showed dif- ) * fuse immunoreactivity of PRL in the tumor cells, his basal PRL levels were within normal ranges. It has been reported that there is no correlation between serum PRL levels and the number of PRL-positive cells [10] . Furthermore, normoprolactinemia was observed in 60% patients with GH-producing pituitary adenoma even with positive immunostaining for PRL [11] . Accordingly, positive immunostaining for PRL in GHproducing pituitary adenomas may not always reflect hyperprolactinemia as in the present case. In addition to the classical acromegalic features compatible with GH-producing pituitary adenoma, the present case showed abnormal regulation of HPA axis; 1) lack of circadian rhythm of ACTH and cortisol, 2) nonsuppressibility to low-dose, but not high-dose dexamethasone, 3) responsiveness to CRH stimulation, 4) improvement of abnormal HPA axis after removal of the tumor, and 5) the presence of immunoreactive ACTH in the resected pituitary tumor. Based on these findings in the absence of Cushingoid features, the diagnosis of subclinical Cushing's disease was made. The slightly high nocturnal plasma cortisol level (6.6 µg/dl) after surgery may suggest the transient impaired HPA axis.
Although the mechanism(s) by which patients with subclinical Cushing's disease do not develop overt Cushing's syndrome remains unknown, several possible mechanisms could be speculated. First, such tumors may predominantly produce biologically inactive ACTH molecules. PC 1/3 which specifically cleaves ACTH(1-39) from precursor molecules, such as proopiomelanocortin and pro-ACTH, has been shown to be absent in clinically silent corticotroph adenoma, whereas pituitary adenomas causing overt Cushing's disease abundantly express PC 1/3 [12] . Since immunostaining for PC 1/3 was negative in the present tumor, it is possible to assume that the impaired PC 1/3 expression may preferentially synthesize and secrete biologically inactive ACTH precursors, thereby partly accounting for the absence of Cushingoid features. However, gel exclusion chromatography was not performed to examine the preferential presence of high molecular weight form of ACTH in the patient's plasma.
Second, the pituitary tumor may secrete ACTH less efficiently than GH by the impaired intracellular secre- tory process, including protein packaging, intracellular trafficking, or exocytosis. Several modulator proteins, such as Rab8b, Rab27b and TRIP8b, have been shown be involved in the regulated secretion of ACTH in AtT20 cells [13, 14] . Thus, any modifications of such modulator proteins, although not proven, may be responsible for the less efficient hormone secretion from the tumors. Third, excessive GH secretion may have masked hypercortisolemia. Previous in vitro and in vivo studies have shown that GH influences cortisol metabolism by modulation of 11 β-hydroxysteroid dehydrogenase type 1 (11βHSD-1) which converts inactive cortisone to active cortisol [15] [16] [17] . 11βHSD-1 activity has been shown to be inhibited by GH excess, resulting in the reduced tissue exposure to glucocorticoids [15, 18] . In fact, it has been reported that the ratio of urinary tetrahydrocortisol (THF)+allo-THF to tetrahydrocortisone (THE) was reduced in acromegalic patients, suggesting the increased metabolic clearance of cortisol [19] . In addition, a rare case of Cushing's disease without the classical phenotype has been reported due to a partial defect in the 11βHSD-1 activity protective against cortisol excess [20] . Although we could not measure urinary THF+allo-THF/THE in the present case, it is possible to assume that excessive GH secretion may have reduced the glucocorticoid effect by inhibiting the conversion of cortisone to cortisol via 11βHSD-1, thereby leading to masking the Cushingoid feature.
Both GH and cortisol, albeit via different mechanisms, share metabolic effects in common [21] [22] [23] [24] . Both hormones induce insulin resistance by suppression of the insulin-mediated glucose uptake in peripheral tissue as well as increase in the hepatic glucose production. Both hormones stimulate lipolysis, lipid oxidation, and mobilization of stored triglyceride. Furthermore, both hormones induce water and sodium retention to cause hypertension [25, 26] . Accordingly, both acromegaly and Cushing's disease present with co-morbidities, such as obesity, hypertension, diabetes, and dyslipidemia, collectively termed the metabolic syndrome. In the present case, after removal of the pituitary tumor, hypertension and diabetes abolished. Thus, GH and/or cortisol excess may be responsible for the development of these metabolic disorders. However, it remains unknown which hormonal excess plays more major role in the development of metabolic comorbidities.
In summary, we report a very rare case of pituitary adenoma producing both GH and ACTH with typical acromegaly and subclinical Cushing's disease, in whom the metabolic co-morbidities, such as diabetes and hypertension, abolished after removal of the pituitary tumor.
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